Search

Your search keyword '"Palou-Redorta, J"' showing total 327 results
Start Over Author "Palou-Redorta, J"
327 results on '"Palou-Redorta, J"'

7. Individual patient data validation of the definitions of BCG failure in patients with non-muscle invasive urothelial carcinoma of the bladder: An international multi-centre retrospective study

Author

Gontero, P., primary, Soria, F., additional, Babjuk, M., additional, Burger, M., additional, Comperat, E., additional, Mostafid, H., additional, Palou Redorta, J., additional, Roupret, M., additional, Van Rhijn, B.W., additional, Zigeuner, R., additional, Shariat, S.F., additional, Cohen, D., additional, Masson-Lecomte, A., additional, Xylinas, E., additional, Mariappan, P., additional, Rai, B.P., additional, Capoun, O., additional, Soukup, V., additional, Thalmann, G., additional, Pradere, B., additional, Seisen, T., additional, Dominguez-Escrig, J.L., additional, Liedberg, F., additional, and Sylvester, R.J., additional

Published
2024
Full Text
View/download PDF

8. Towards defining follow-up strategies for patients with primary (first diagnosis) EAU2021 intermediate-risk non-muscle invasive bladder cancer

Author

Contieri, R., primary, Beijert, I., additional, Martini, A., additional, Camperat, E.M., additional, Hernandez, V., additional, Bruins, H.M., additional, Dominguez-Escrig, J.L., additional, Liedberg, F., additional, Masson-Lecomte, A., additional, Cohen, D., additional, Mostafid, H., additional, Shariat, S.F., additional, Roupret, M., additional, Pradere, B., additional, Zigeuner, R., additional, Soria, F., additional, Soukup, V., additional, Palou Redorta, J., additional, Capoun, O., additional, Burger, M., additional, Gontero, P., additional, Sylvester, R., additional, Mertens, L., additional, and Van Rhijn, B.W.G., additional

Published
2024
Full Text
View/download PDF

10. Usefulness of renal nephrometry scoring systems in the prediction of complications associated to percutaneous image-guided treatment for small renal masses

Author

Abu-Suboh Abadia, A., primary, Abu-Suboh Abadia, A., additional, Mosquera Seoane, L., additional, Gómez Martínez, P., additional, Trillo Lista, M.A., additional, Portela Pereira, P., additional, Martínez Barcina, M.J., additional, Palou Redorta, J., additional, and Rodríguez Faba, O., additional

Published
2023
Full Text
View/download PDF

15. Diagnóstico incidental del cáncer de vejiga en España. Estudio observacional a nivel nacional

Author

Gaya, J.M., primary, Territo, A., additional, Woldu, S., additional, Schwartzmann, I., additional, Verri, P., additional, González-Pérez, L., additional, Cózar, J.M., additional, Miñana, B., additional, Medina, R.A., additional, de la Rosa-Kehrmann, F., additional, Lozano-Palacio, F., additional, Ribal, M.J., additional, Hernández, C., additional, Castiñeiras, J.J., additional, Requena, M.J., additional, Moreno, J., additional, Caraballido, J.A., additional, Baena, V., additional, Breda, A., additional, and Palou Redorta, J., additional

Published
2022
Full Text
View/download PDF

18. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guerin-exposed High-risk Non-muscle-invasive Bladder Cancer

Author

Roumiguie, M, Kamat, AM, Bivalacqua, TJ, Lerner, SP, Kassouf, W, Bohle, A, Brausi, M, Buckley, R, Persad, R, Colombel, M, Lamm, D, Palou-Redorta, J, Soloway, M, Brothers, K, Steinberg, G, Lotan, Y, Sylvester, R, Witjes, JA, and Black, PC

Subjects
Clinical trials, Non-muscle-invasive bladder cancer, Intravesical therapy, Bacillus Calmette-Guerin, Risk stratification
Abstract

Context: A large proportion of patients with non-muscle-invasive bladder cancer (NMIBC) fall in the gap between bacillus Calmette-Guerin (BCG)-naive and BCG-unresponsive disease. As multiple therapeutic agents move into this gray area, there is a critical need to define the disease state and establish recommendations for optimal trial design. Objective: To develop a consensus on optimal trial design for patients with BCG-exposed NMIBC, defined as high-grade recurrence after BCG treatment that does not meet the criteria for BCG-unresponsive disease. Evidence acquisition: We conducted a literature review using the Cochrane Library, Medline, and Embase and a review of clinical trials in ClinicalTrials.gov as a basis to generate consensus recommendations for clinical trial design in BCG-exposed NMIBC. Evidence synthesis: BCG-exposed NMIBC encompasses BCG resistance (presence of high-grade Ta or carcinoma in situ [CIS] at 3-mo evaluation after induction BCG) and delayed relapse. Randomized controlled trials are required to compare experimental therapies to a control arm receiving additional BCG, although ongoing BCG shortages may impact our ability to follow an optimal trial design. A placebo should be used in combination with BCG if the treatment arm includes BCG plus a study drug. Trials will either need to separate patients with and without CIS into two cohorts, or stratify by the presence of CIS at the time of randomization. If two cohorts are used, the primary endpoint for CIS patients should be complete response within a predetermined time. The primary endpoint in a cohort with Ta/T1 only, or if a single combined cohort is used, should be the duration of event-free survival. Suggested efficacy thresholds and corresponding sample sizes are provided. Conclusions: The International Bladder Cancer Group has developed recommendations regarding definitions, endpoints, and clinical trial design for BCG-exposed NMIBC to encourage uniformity among studies in this disease state. Patient summary: Our consensus provides a precise definition of the disease state for bladder cancer not invading the bladder muscle and exposed to bacillus Calmette-Guerin (BCG) treatment. Clear guidance for conducting optimal clinical trials in this disease setting was established and we believe that this will promote further progress in this field. (C) 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Published
2022

19. Assessing the impact of BCG on progression of NMIBC in the new EAU high risk and very high-risk groups

Author

Gontero, P., primary, Dominguez-Escrig, J.L., additional, Van Rhijn, B.W.G., additional, Mostafid, A.H., additional, Roupret, M., additional, Cohen, D., additional, Comperat, E., additional, Liedberg, F., additional, Palou Redorta, J., additional, Burger, M., additional, Shariat, S., additional, Seisen, T., additional, Soukup, V., additional, Masson-Lecomte, A., additional, Capoun, O., additional, Babjuk, M., additional, and Sylvester, R.J., additional

Published
2022
Full Text
View/download PDF

22. Diagnóstico incidental del cáncer de vejiga en España. Estudio observacional a nivel nacional

Author

Gaya, J.M., Territo, A., Woldu, S., Schwartzmann, I., Verri, P., González-Pérez, L., Cózar, J.M., Miñana, B., Medina, R.A., de la Rosa-Kehrmann, F., Lozano-Palacio, F., Ribal, M.J., Hernández, C., Castiñeiras, J.J., Requena, M.J., Moreno, J., Caraballido, J.A., Baena, V., Breda, A., and Palou Redorta, J.

Abstract

El cáncer de vejiga (CV) es una neoplasia frecuente en España. Los objetivos de este estudio fueron: identificar la proporción de pacientes diagnosticados de CV de forma incidental o tras la presentación de síntomas en un periodo contemporáneo en España; comparar las características demográficas, clínicas y patológicas entre estos grupos.

Published
2023
Full Text
View/download PDF

24. Endoscopic exploration directly impacts clinical decision making in the management of patients with suspected upper tract urothelial carcinoma following radical cystectomy

Author

Aumatell Ovide, J., primary, Huguet Pérez, J., additional, Subiela, J.D., additional, Mercadé Sánchez, A., additional, Balañà Lucena, J., additional, Gaya Sopena, J.M., additional, Rodríguez-Faba, O., additional, Territo, A., additional, Breda, A., additional, and Palou Redorta, J., additional

Published
2021
Full Text
View/download PDF

26. Flexible ureteroscopy in extreme elderly patients (80 years of age and older)

Author

Emiliani, E., primary, Piccirilli, A., additional, Cepeda-Delgado, M., additional, Kanashiro, A.K., additional, Mantilla, D., additional, Amaya, C.A., additional, Sanchez-Martin, F.M., additional, Rodriguez, F.Millán, additional, Territo, A., additional, Sesmero, J.H.Amón, additional, Palou-Redorta, J., additional, and Angerri-Feu, O., additional

Published
2020
Full Text
View/download PDF

27. Flexible ureteroscopy in extreme elderly patients (80 years of age and older) is feasible and safe

Author

Emiliani, E., primary, Piccirilli, A., additional, Cepeda-Delgado, M., additional, Kanashiro, A. K., additional, Mantilla, D., additional, Amaya, C. A., additional, Sanchez-Martin, F. M., additional, Millan-Rodriguez, F., additional, Territo, A., additional, Amón-Sesmero, J. H., additional, Palou-Redorta, J., additional, and Angerri-Feu, O., additional

Published
2020
Full Text
View/download PDF

29. Nomogram including maximum core length at biopsy and index lesion size at mpMRI best predicts the extra-capsular extension of prostate cancer at whole-mount sections of radical prostatectomies

Author

Sanguedolce, F., primary, Subiela Henriquez, J.D., additional, Granados Palacio, L., additional, Hernandez Mancera, J., additional, Martinez Barcina, M.J., additional, Calderon Cortez, J., additional, Territo, A., additional, Esquina Lopez, C., additional, Gaya, J.M., additional, Huguet, J., additional, Palou Redorta, J., additional, and Breda, A., additional

Published
2020
Full Text
View/download PDF

30. Effectiveness of glycosaminoglycan replacement treatment with intravesical instillation in patients with haemorrhagic radiation cystitis post-pelvic radiotherapy

Author

Sanguedolce, F., primary, Meneghetti, J., additional, Montaño, B., additional, Bevilacqua, G., additional, Martinez, C., additional, Saitta, G., additional, Territo, A., additional, Balaña, J., additional, Gaya, J.M., additional, Huguet, J., additional, Palou Redorta, J., additional, and Breda, A., additional

Published
2020
Full Text
View/download PDF

31. PD21-06 MULTICENTRE INTERNATIONAL STUDY FOR THE PREVENTION WITH HYALURONIC ACID – CHONDROITIN SULPHATE OF RADIO-INDUCED CYSTITIS (MISTIC)

Author

Lazzeri*, Massimo, primary, Vittori, Gianni, additional, Casale, Paolo, additional, Buffi, Nicolo Maria, additional, Maida, Fabrizio Di, additional, Romancik, Martin, additional, Lunik, Richard, additional, Colombo, Renzo, additional, Bini, Vittorio, additional, Sanguedolce, Francesco, additional, Palou, Redorta j, additional, Minervini, Andrea, additional, and Carini, Marco, additional

Published
2020
Full Text
View/download PDF

37. Eficacia y seguridad de la inyección de onabotulinumtoxin A en pacientes varones con hiperactividad del detrusor tras la cirugía para incontinencia urinaria de esfuerzo

Author

Mateu-Arrom, L., Gutiérrez-Ruiz, C., Sabiote Rubio, L., Martínez Barea, V., Palou Redorta, J., and Errando-Smet, C.

Abstract

El uso de la inyección de onabotulinumtoxin A (BoNT-A) en pacientes masculinos con hiperactividad del detrusor (HD) tras la cirugía para la incontinencia urinaria de esfuerzo (IUE) ha sido escasamente descrito. Nuestro objetivo fue evaluar los resultados de este tratamiento en esta población específica.

Published
2022
Full Text
View/download PDF

38. Development and validation of the non-technical skills for urological surgeons (NoTSUS) ureteroscopy scenario curriculum

Author

Aydin, A., primary, Brunckhorst, O., additional, Raison, N., additional, Brewin, J., additional, Mcilhenny, C., additional, Al-Jabir, A., additional, Aya, H., additional, Dar, F., additional, Iqbal, M., additional, Lovegrove, C., additional, Shabbir, M., additional, Brouwers, T., additional, Palou Redorta, J., additional, Khan, M., additional, Dasgupta, P., additional, and Ahmed, K., additional

Published
2018
Full Text
View/download PDF

39. Radiation cystitis after prostate cancer radiotherapy: Risk factors associated to hospital admission and intervention

Author

Sanguedolce, F., primary, Pisano, F., additional, Sancho Pardo, G., additional, Acosta, E., additional, Mercadé Sanchez, A., additional, Balaña Lucena, J., additional, Breda, A., additional, Territo, A., additional, Basile, G., additional, Vila, H., additional, Rodriguez Faba, O., additional, and Palou Redorta, J., additional

Published
2018
Full Text
View/download PDF

42. Documento de consenso sobre las implicaciones de la normalización del suministro del BCG en el manejo del paciente con tumor vesical no-músculo invasivo (TVNMI)

Author

Rodríguez Faba, Ó., Fernández Gómez, J.M., Guerrero-Ramos, F., Álvarez-Maestro, M., Ledo Cepero, M.J., Unda Urzaiz, M., Martínez-Piñeiro, L., Cózar Olmo, J.M., Palou Redorta, J., and Álvarez-Ossorio, J.L.

Abstract

Los pacientes con tumor vesical no-músculo invasivo (TVNMI) de los grupos de riesgo intermedio y alto deben ser tratados con el bacilo de Calmette-Guérin (BCG) intravesical adyuvante después de la resección transuretral (RTU), ya que dicho tratamiento disminuye el riesgo de recurrencia y, probablemente también, el de progresión. La optimización de la eficacia del BCG se consigue administrando un tratamiento de mantenimiento. Sin embargo, dado que se desconocen muchos detalles inmunológicos del mecanismo de acción del BCG en la vejiga, la implementación a lo largo de las últimas décadas de la dosis óptima, número de instilaciones, cepas y régimen adecuado de mantenimiento, se ha realizado de manera heterogénea, lo que ha generado dificultades para interpretar los resultados de eficacia oncológica. Esto unido con el desabastecimiento del BCG que se ha sufrido en los últimos años, ha hecho que las diferentes sociedades científicas tengan que adaptar sus guías de práctica clínica a esta situación, modificando durante este tiempo sus protocolos de tratamiento adyuvante con el BCG con relación a las cepas, a la dosis y al mantenimiento. En este documento de consenso, se evalúa el estado actual del tratamiento adyuvante con el BCG y las implicaciones de la normalización del suministro del BCG en el tratamiento oncológico de los pacientes con TVNMI, así como la implementación de nuevos tratamientos que en el futuro mejoren el pronóstico oncológico y la calidad de vida de los pacientes con TVNMI.

Published
2024
Full Text
View/download PDF

46. Factors that predict the development of bone metastases due to prostate cancer: Recommendations for follow-up and therapeutic options

Author

Rodriguez-Antolin, A, Gomez-Veiga, F, Alvarez-Osorio, JK, Carballido-Rodriguez, J, Palou-Redorta, J, Solsona-Narbon, E, Sanchez-Sanchez, E, and Unda, M

Subjects
Prostate cancer, Follow-up, Bone metastasis, Local disease, Prognostic factors, Hormone therapy
Abstract

Context: Prostate cancer is a public health problem in Spain and in the Western world. Bone involvement, associated to significant morbidity, is practically constant in the advanced stages of the disease. This work aims to review the prognostic factors used in the usual clinical practice that predict the development of bone metastases and to analyze the follow-up and treatment option in these patient profiles. Acquiring of evidence: We performed a review of the literature on the useful factors in the context of therapy with intention to cure. We included the classical clinical values in the diagnosis (PSA, clinical stage, Gleason score on the biopsy) pathological factors (pT stage, margins, bladder invasion, tumor volume, lymph node involvement) and PSA kinetics in their different contexts and the histological and molecular parameters. Synthesis of evidence: The tumor differentiation Gleason score and PSA are the most important predictive factors in the prediction of bone metastases in patients with intention to cure. Kinetic factors such as PSA doubling time (TDPSA) 10 ng/ml in the case of castration-resistant prostate cancer (CPRC), are predictive factors for the development of metastasis. Zoledronic acid and denosumab have demonstrated their effectiveness for the treatment of bone disease in randomized studies. Conclusions: There are predictive factors within the usual clinical practice that make it possible to recognize the "Patient at risk" to develop bone metastatic disease. The currently available treatments, zoledronic acid or denosumab, can help us in the management of the patient at risk of developing metastasis or metastatic patient, increasing the quality of life and decreasing skeletal events. (C) 2013 AEU. Published by Elsevier Espana, S.L. All rights reserved.

Published
2014

50. Matrix Metalloproteinases and Bladder Cancer: What is New?

Author

Rodriguez Faba, O., Palou-Redorta, J., Fernández-Gómez, J. M., Algaba, F., Eiró, N., Villavicencio, H., and Vizoso, F. J.

Subjects
Article Subject
Abstract

Urothelial bladder cancer represents a heterogeneous disease with divergent pathways of tumorigenesis. Tumor invasion and progression are a multifactorial process promoted by microenvironmental changes that include overexpression of matrix metalloproteinases (MMPs). Recent data clearly challenge the classic dogma that MMPs promote metastasis only by modulating the remodeling of extracellular matrix. Indeed, MMPs have also been attributed as an impact on tumor cell behavior in vivo as a consequence of their ability to cleave growth factors, cell surface receptors, cell adhesion molecules, and chemokines/cytokines. Levels of the different MMPs can be measured in several sample types, including tissue, blood (serum and plasma), and urine, and using different methodologies, such as immunohistochemistry, real-time PCR, western and northern blot analyses, enzyme-linked immunosorbent assay, and zymography. Several MMPs have been identified as having potential diagnostic or prognostic utility, whether alone or in combination with cytology. Although MMP inhibitors have shown limited efficacy, advances in the understanding of the complex physiologic and pathologic roles of MMPs might permit the development of new MMP-specific and tumor-specific therapies. In this paper we update the understanding of MMPs based on a systematic PubMed search encompassing papers published up to December 2011.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results